These results raise the question whether an increase of EPC, MSC, VEGF or Ang2 could beneficially influence the clinical course of ARDS patients undergoing ECMO, which needs to be addressed in future studies. This evidence concerns the gene VEGFA and acute respiratory distress syndrome.